Trump Speeds FDA Reviews for Psychedelics
April 20, 2026·18 days ago·via Pharmaceutical Executive
President Trump signs an executive order directing the FDA to accelerate reviews for psychedelic drugs, cutting through bureaucratic red tape that has stifled innovation for too long. This bold move prioritizes American patients and researchers over globalist regulations and big-government delays, potentially unlocking treatments for mental health crises ravaged by opioid epidemics and lockdown fallout. Read more about this...